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A B S T R A C T
Post mortem brain studies indicate that alterations in serotonergic and catecholaminergic systems might be associ-
ated with Alzheimer’s disease (AD). The aim of the study was to determine serotonin (5-HT) levels and monoamine
oxidase type B (MAO-B) activity in platelets of psychotic and non-psychotic patients with AD, established according to the
NINCDS-ADRDA and DSM-IV-TR criteria. Cognitive impairment and psychotic features were evaluated using Mini
Mental Status Examination and Neuropsychiatric Inventory. Platelet 5-HT concentration and MAO-B activity were de-
termined spectrofluorimetrically in 116 (51 male, 65 female) healthy subjects and 70 psychotic (10 male, 60 female) and
151 non-psychotic (32 male, 119 female) patients. Psychotic and non-psychotic female and psychotic male patients had
significantly lower platelet 5-HT concentration than corresponding sex matched control subjects. Platelet MAO-B activ-
ity was significantly increased in both male and female non-psychotic patients compared to the sex matched controls.
Non-psychotic female patients had significantly higher platelet MAO-B activity than psychotic female patients. Our data
suggest that platelet MAO-B activity, but not platelet 5-HT concentration, could differentiate between psychotic and non-
-psychotic subtypes of AD.
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Introduction
Alzheimer’s disease (AD) is a complex neurodege-
nerative disorder with different cognitive and behav-
ioural abnormalities1. Various studies have found that
majority of AD patients suffer from psychotic symptoms,
like auditory and/or visual hallucinations and delusions2.
Psychotic features upset the patients, complicate the
treatment response, and are frequently associated with
the rapid progress of the disease2.
The aetiology of AD is still not clear. Post mortem
brain studies in patients with AD3 showed neuropatho-
logical and neurochemical alterations in catecholaminer-
gic4 and serotonergic5 systems. The decrease in brain
dopamine6, serotonin (5-hydroxytryptamine, 5-HT)6, and
its main metabolite 5-hydroxyindoleacetic acid (5-HIAA)
concentrations, and the loss of 5-HT2 receptors7, was
found in patients with AD. Blood platelets have been pro-
posed as an easy obtainable peripheral model for some
processes in the central serotonergic neurons8–10 and for
the expression of the brain amyloid precursor protein11.
The studies on platelet 5-HT uptake12,13, and platelet
monoamine oxidase type B (MAO-B) in AD yielded in-
consistent results14. MAO is a flavin-containing oxygen
oxidoreductase. Two isoenzymes (MAO-A and MAO-B)
differ in localization, substrates and inhibitors15. MAO-B
exists in platelets, astrocytes and 5-HT neurons. Its sub-
strates are b-phenylethylamine, benzylamine, dopamine,
tyramine, and tryptamine, and its inhibitor is deprenyl15.
It is assumed that altered levels of platelet MAO-B are
associated with different psychopathologies and vulnera-
bility to psychiatric disorders15,16. An increase in platelet
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MAO-B activity was observed in AD17. Recently we have
found18 that platelet MAO-B activity might be used as a
peripheral biomarker for the early and late onset AD.
We have previously found that platelet 5-HT might
differentiate between psychotic and non-psychotic de-
pression19, posttraumatic stress disorder (PTSD)20, bipo-
lar affective disorder in a manic phase21. In addition, a
higher platelet MAO-B activity was found in psychotic
compared to non-psychotic subtype of PTSD22. The hy-
pothesis of the present study was that platelet biochemi-
cal markers would differ in AD patients with or without
psychotic features. The aim of the present study was to
determine peripheral biochemical markers (platelet 5-HT
concentration and platelet MAO-B activity) in male and
female patients with AD, subdivided according to the
presence of psychotic features, and in sex matched heal-
thy controls.
Subjects and Methods
The study included 221 (42 male, 179 female) medica-
tion-free patients (mean age 60.6±9.9 years) with AD,
hospitalized in Psychiatric Hospital Vrap~e, Zagreb. The
diagnosis of the probable AD (NINCDS-ADRDA crite-
ria23) was established by two psychiatrists according to
the DSM-IV-TR criteria24. Cognitive impairment was eval-
uated using Mini Mental Status Examination (MMSE)25.
Mean MMSE scores in AD patients was 18.9±3.2. Accord-
ing to the Neuropsychiatric Inventory26, patients were
subdivided into two groups: 70 patients (10 male and 60
female) with psychotic features and 151 patients (32
male, 119 female) without psychotic features. Control
group consisted of sex and age-matched, medication-free
healthy subjects (65 female, 51 male) (mean age 60.3±
11.2 years), with no history of psychiatric illness. All sub-
jects were nonsmokers. The study was approved by the
Ethic committee and all participants gave informed con-
sent.
Blood samples (8 mL) were obtained from a jugular
vein, after an overnight fasting, in a plastic syringe with
2 ml of acid citrate dextrose anticoagulant. Platelet rich
plasma (PRP) was obtained after centrifugation of whole
blood, and platelets were sedimented by further centri-
fugation of PRP. Platelet 5-HT concentration was deter-
mined by the spectrofluorimetric method, as previously
described27, using Varian Cary Eclipse spectrofluorime-
ter Platelet MAO-B activity was determined spectro-
fluorimetrically using kynuramine as a substrate27,28.
Platelet protein levels were measured by the method of
Lowry et al.29.
The results were expressed as mean±SD. The differ-
ences between groups were analyzed using Kruskal-
–Wallis one-way analysis of variance (ANOVA) by ranks
followed by Mann-Whitney rank sum test for pairwise
comparisons. The statistical package used was Statistica 6
and SPSS 10.0 analysis.
Results
Platelet 5-HT concentration was significantly (H=
36.5, df=5, p<0.001; Kruskal Wallis ANOVA) different
among healthy controls and patients with AD, subdi-
vided according to the presence of psychotic features
(Figure 1). A significant decrease in platelet 5-HT con-
centration was observed in psychotic (p=0.002, Mann
Whitney test) and non-psychotic (p<0.001) female pa-
tients and non-psychotic (p=0.002) male patients com-
pared to platelet 5-HT concentration in corresponding
sex-matched healthy controls. There was no significant
difference in platelet 5-HT concentration between male
(p=0.712, Mann Whitney test) or female (p=0.422, Mann
Whitney test) psychotic or non-psychotic AD patients.
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Fig. 1. Platelet serotonin (5-HT) in male and female healthy con-
trols and patients with Alzheimer’s disease (AD) with or without
psychotic features. *p=0.002 vs. healthy male; **p=0.002 vs. heal-
thy female; #p<0.001 vs. healthy female (Kruskal Wallis ANOVA
on ranks followed by Mann Whitney test)
Fig. 2. Platelet monoamine oxidase (MAO) in healthy controls
and patients Alzheimer’s disease (AD) with or without psychotic
features. *p=0.017 vs. female psychotic patients; **p<0.006 vs.
healthy male; #p<0.001 vs healthy female (Kruskal Wallis ANOVA
on ranks followed by Mann Whitney test)
Platelet MAO-B activity differed significantly (H=
28.8, df=5, p<0.001, Kruskal Wallis ANOVA) in patients
with AD, subdivided into groups with or without psy-
chotic features, and in healthy control subjects (Figure
2). Platelet MAO-B activity was significantly higher in
both male (p<0.006) and female (p<0.001) non-psycho-
tic patients with AD than in sex matched healthy con-
trols. Non-psychotic female AD patients had significantly
(p<0.017) higher platelet MAO-B activity than psychotic
female AD patients. There was no significant difference
(p=0.73, Mann Whitney test) in platelet MAO activity
between psychotic and non-psychotic male AD patients.
Discussion
The results of the present study show that patients
with AD have different platelet 5-HT concentration and
platelet MAO-B activity when compared to sex- and
age-matched control subjects. To our knowledge this is
the first report showing a decreased platelet 5-HT con-
centration in patients with AD. Although platelets repre-
sent a limited peripheral model for the central serotoner-
gic neurons, it is noteworthy that similar reductions in
5-HT and 5-HIAA concentrations have also been found
in the areas of the frontal and temporal cortices of AD
patients5. In addition, our results showed that the alter-
ations in platelet 5-HT values in AD patients were not re-
lated to the presence of psychotic features. This result is
in contrast with the increased platelet 5-HT concentra-
tions in psychotic unipolar depressed patients19, bipolar
patients in manic phase21, war veterans PTSD with psy-
chotic symptoms20, or schizophrenic patients with pre-
dominantly positive symptoms30, when compared to cor-
responding control subjects.
The discrepancies in platelet 5-HT concentration in
patients with AD might be explained by the various fac-
tors, including a decrease in 5-HT synthesis, an increase
in 5-HT metabolism and a change in 5-HT transporter. It
has been suggested31 that aging may be associated with
lower activity of the tryptophan hydroxylase, a rate lim-
iting enzyme in 5-HT synthesis. Since our study included
age matched patients and control subjects, the difference
in platelet 5-HT values between groups is presumably
not related to the difference in age of the subjects.
Platelet 5-HT transporter is the most important mem-
brane protein, responsible for the active transport of
5-HT from plasma into platelets, and consequently for
platelet 5-HT concentrations. However, recent molecular
study32 did not find an association between a deletion/in-
sertion polymorphism within promoter region of the
5-HT transporter gene and AD.
Although blood platelets contain only MAO type B,
which is not entirely specific for the metabolism of the
5-HT, we can not exclude the possibility that the decrease
in platelet 5-HT concentrations in patients with AD is in
part a consequence of the higher platelet MAO -B activity.
In the present study we have found an increase in
platelet MAO-B activity in both male and female patients
with AD compared to control subjects. This is in line with
our previous finding of the high platelet MAO-B activity
in patients with early onset AD, and with other studies
showing increased MAO activity in brain14,33 and pla-
telets14,17,18,34 of patients with AD. In addition, we have
found that the increase in platelet MAO-B activity was
restricted only to patients without psychotic features.
Several factors such as sex, smoking, age, race, some
neurodegenerative disorders, pernicious anaemia, and
psychotropic drugs15 affect platelet MAO-B activity. To
control for these variables, we subdivided patients ac-
cording to the sex, they were matched for race, age, and
medication, and none of the patients were smokers.
Higher platelet MAO-B activity reported in our non-psy-
chotic AD patients might be connected with some hidden
psychopatologies15, personality traits35,36, such as neuro-
ticism37 or high anxiety36. The increased platelet MAO-B
activity in non-psychotic AD patients does not agree with
the recent finding of an elevated activity of platelet
MAO-B in war veterans PTSD with psychotic symp-
toms22when compared to corresponding control subjects.
This discrepancy might be due to the differences in diag-
noses (AD vs. PTSD), age15 or smoking20. In addition, al-
tered platelet MAO-B activity may be related to differ-
ence in yet unknown transcriptional factor(s)38, rather
than genotypic variation22, that act on transcriptional
regulation38 of the amount of enzyme and/or in the ki-
netic regulation of the molecular activity of MAO-B in
platelets39.
Our results of the increased MAO-B activity in AD pa-
tients support the presumption that neurotoxic and reac-
tive metabolites of catecholamine neurotransmitters
could be involved in the aetiology and progress of AD. Re-
cently, neurotoxicity of MAO-B metabolites of noradre-
nalin, adrenaline or dopamine has been shown in vitro
and in vivo40. The serious consequence of the altered
MAO activity is the increase in catecholamine metabo-
lites like 3, 4-dihydroxyphenylglycholaldehyde (DOPE-
GAL) and 3,4-dihydroxyphenylacetaldehyde (DOPAL),
which are highly reactive and toxic to neuronal cells in
vitro and in vivo40.
In conclusion, we have found altered biochemical pa-
rameters in platelets of patients with AD. Our results of
decreased platelet 5-HT concentrations and increased
platelet MAO-B activity suggest that both serotonergic
and catecholaminergic system could be involved in the
pathophysiology and progress of AD. In addition, platelet
MAO-B activity, but not 5-HT concentration, might be
used as a peripheral biological marker that can distin-
guish between psychotic and non-psychotic subtypes of
AD.
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TROMBOCITNI SEROTONIN I MONOAMINOOKSIDAZA B U BOLESNIKA
S AZHEIMEROVOM BOLESTI SA PSIHOTI^KIM SIMPTOMIMA
S A @ E T A K
Post mortem istra`ivanja su pokazala promjene serotoninskog i kateholaminskog sustava u mozgu oboljelih od Alz-
heimerove bolesti (AB). Cilj istra`ivanja bio je odrediti koncentraciju trombocitnog serotonina (5-HT) i aktivnost trom-
bocitne monoaminooksidaze tipa B (MAO-B) u bolesnika s AB sa ili bez psihoti~nih simptoma i u skupini zdravih osoba.
Dijagnoza vjerojatne AB (NINCDS-ADRDA kriterij) postavljena je u skladu s DSM-IV kriterijima. Za procjenu kogni-
tivnog o{te}enja kori{tena je Mini Mental Status Examination, a za odre|ivanje psihoti~nih simptoma Neuropsychiat-
ric Inventory. U trombocitima 116 zdravih osoba (51mu{karaca, 65 `ena), 70 bolesnika (10 mu{karaca, 60 `ena) sa
psihoti~kim simptomima i 151 bolesnika (32 mu{karca, 119 `ena) bez psihoti~kih simptoma odre|ena je koncentracija
5-HT i aktivnost MAO-B pomo}u spektrofluorimetrijskih metoda. Koncentracija trombocitnog 5-HT bila je zna~ajno
sni`ena u bolesnica sa psihoti~kim i nepsihoti~kim simptomima te u nepsihoti~kih bolesnika u odnosu na koncentraciju
trombocitnog 5-HT u odgovaraju}oj skupini zdravih `ena i mu{karaca. Aktivnost trombocitne MAO-B bila je pove}ana
u mu{kih i `enskih nepsihoti~kih bolesnika s AB u usporedbi s aktivno{}u u zdravoj kontroli odgovaraju}eg spola. U
trombocitima nepsihoti~kih `enskih bolesnica prona|ena je zna~ajno pove}ana aktivnost MAO-B u odnosu na aktiv-
nost enzima u trombocitima bolesnica sa psihoti~kim simptomima. Rezultati istra`ivanja upu}uju da bi aktivnost trom-
bocitne MAO-B mogla biti biokemijski pokazatelj za razlikovanje psihoti~kog i nepsihoti~kog oblika AB.
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